The Journal of Pediatrics
Volume 148, Issue 6 , Pages 831-834 , June 2006

Severe liver injury after initiating therapy with atomoxetine in two children

  • Joel R. Lim, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Joel R. Lim, M.D., Assistant Professor of Clinical Pediatrics, Division of Pediatric Gastroenterology/Hepatology/Nutrition, James Whitcomb Riley Hospital for Children, Indiana University School of Medicine, 702 Barnhill Drive, Room ROC 4210, Indianapolis, Indiana 46202-5225.
    • ,
  • Philip R. Faught, MD
    • ,
  • Naga P. Chalasani, MD
    • ,
  • Jean P. Molleston, MD

Received 8 April 2005 ,Revised 21 October 2005 ,Accepted 10 January 2006.

References 

  1. US Food and Drug Administration. Available at http://www.fda.gov/medwatch/SAFETY/2004/Strattera_PI.pdf. Accessed March 2005.
  2. Ring BJ , Gillespie JS , Eckstein JA , Wrighton SA . Identification of the human Cytochromes P450 responsible for atomoxetine metabolism . Drug Metab Dispos . 2002;30:319–323
  3. Guengerich FP. Human cytochrome P450 enzymes. In Ortix de Montellano PR, ed. Cytochrome P450: Structure, Mechanism and Biochemistry. 2nd ed. New York: Plenum Press:473–535.
  4. Westphal JF, Brogard JM. Antibacterials and antifungal agents. In Kaplowitx N, DeLeve LD, eds. Drug Induced Liver Disease. 1st ed. New York: Marcel Dekker, Inc.:471–504.
  5. Sauer J , Ring B , Witcher JW . Clinical pharmacokinetics of atomoxetine . Clin Pharmacokinet . 2005;44:571–590
  6. Zimmerman HJ . Drug-induced liver disease . Clin Liver Diseases . 2000;4:73–96
  7. US Food and Drug Administration. Available at http://www.fda.gov/cder/foi/label/2002/214 11_strattera_lbl.pdf. Accessed June 2004.
  8. Dan G , Benichou C . Causality assessment of adverse reaction to drugs: a novel method based on the conclusions of international consensus meetings: application to drug induced liver injury . J Clin Epidemiol . 1993;46:1323–1330
  9. Benichou C , Danan G , Flahault A . Causality assessment of adverse reactions to drugs, II: an original model for validation of drug causality assessment methods: case reports with positive rechallenge . J Clin Epidemiol . 1993;46:1331–1336
  10. Siddiqui J , Raina D , Abraham A , Alla V , Chalasani N , Wu GY , et al.   Autoimmune hepatitis induced by statins . Gastroenterology . 2005;128:A171
  11. Thiim M , Friedman LS . Hepatotoxicity of antibiotics and anti-fungals . Clin Liver Disease . 2003;7:381–399
  12. Villeneuve JP , Pichette V . Cytochrome P-450 and liver disease . Curr Drug Metab . 2004;5:273–282
  13. Sugimura T , Obermayer-Straub P , Kayser A , Braus S , Loges S , Alex B , et al.   A major CYP2D6 autoepitope in autoimmune Hepatitis type 2 and chronic hepatitis C (is there a three-dimensional structure homologous to other cytochrome P450 autoantigens?) . Autoimmunity . 2002;35:501–513
  14. Rizzetto M , Swana G , Doniach D . Microsomal antibodies in active chronic hepatitis and other disorders . Clin Exp Immunol . 1973;15:331–344
  15. Alvarez F , Bernard O , Homber JC , Kreibich G . Anti-liver kidney microsomal antibody recognizes a 50,000 molecular weight protein of the endoplasmic reticulum . J Exp Med . 1985;161:1231–1236
  16. Liu ZX , Kaplowitz N . Immune-mediated drug-induced liver disease . Clin Liver Dis . 2002;6:735–774
  17. US Food and Drug Administration. Available at http://www.fda.gov/bbs/topics/answers/2004/ANSO1335.html. Accessed March 2005.
  18. Eli Lilly. Available at http://www.lillytrials.com/results_files/Strattera_summary_4642.pdf. Accessed February 2005.
  19. Safer DJ , Zito JM , Gardner JF . Pemoline hepatotoxicity and post-marketing surveillance . J Am Acad Child Adolesc Psychiatry . 2001;40:622–629

PII: S0022-3476(06)00014-X

doi: 10.1016/j.jpeds.2006.01.035

The Journal of Pediatrics
Volume 148, Issue 6 , Pages 831-834 , June 2006

Article Tools

* Image Usage & Resolution